Rossana Lazcano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rossana Lazcano has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Edwin Roger Parra
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
41 shared publications - Ignacio Ivan Wistuba
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
41 shared publications - Jianhua Zhang
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
40 shared publications - Xingzhi Song
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
40 shared publications - Alexander Joseph Lazar
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
33 shared publications - Davis R. Ingram
Department of Pathology, Division of Pathology & Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
33 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
Anatomic location of ST-LMS and RNase H2 status. Absolute number and frequency of cases of RNase H2 loss in the ST-LMS cohort based on primary anatomic location.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
Anatomic location of ST-LMS and RNase H2 status. Absolute number and frequency of cases of RNase H2 loss in the ST-LMS cohort based on primary anatomic location.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
Survival data of U-LMS based on RNase H2 status and RNASEH2B/RB1 HomDel status A) Overall survival of U-LMS patients based on loss of RNase H2 (n=23) or intact RNase H2 (n=85) by IHC B) Overall survival of ULMS patients with or without RNASEH2B HomDels, based on the presence or absence of RB1 HomDels.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
Survival data of U-LMS based on RNase H2 status and RNASEH2B/RB1 HomDel status A) Overall survival of U-LMS patients based on loss of RNase H2 (n=23) or intact RNase H2 (n=85) by IHC B) Overall survival of ULMS patients with or without RNASEH2B HomDels, based on the presence or absence of RB1 HomDels.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
SNiPDx results of U-LMS and ST-LMS samples in the MDACC cohort, with RNase H2 IHC status also reported.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
SNiPDx results of U-LMS and ST-LMS samples in the MDACC cohort, with RNase H2 IHC status also reported.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
Biallelic alterations in other DDR genes across all sarcomas in TCGA dataset. Assessment of the number of sarcomas with biallelic alterations in other DDR pathway members.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
Biallelic alterations in other DDR genes across all sarcomas in TCGA dataset. Assessment of the number of sarcomas with biallelic alterations in other DDR pathway members.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
This file contains 6 supplementary tables referred to in the text of the manuscript
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
This file contains 6 supplementary tables referred to in the text of the manuscript
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
This file contains the description of supplementary materials and methods that is referred to in the manuscript
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
This file contains the description of supplementary materials and methods that is referred to in the manuscript
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figures and Figure legends from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
This File contains all the supplemental figures and figure legends referred to in the main text.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figures and Figure legends from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
This File contains all the supplemental figures and figure legends referred to in the main text.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
Treatment strategies with a strong scientific rationale based on specific biomarkers are needed to improve outcomes in patients with advanced sarcomas. Suppression of cell-cycle progression through reactivation of the tumor suppressor retinoblastoma (Rb) using CDK4/6 inhibitors is a potential avenue for novel targeted therapies in sarcomas that harbor intact Rb signaling. Here, we evaluated combination treatment strategies (sequential and concomitant) with the CDK4/6 inhibitor abemacicib to identify optimal combination strategies. Expression of Rb was examined in 1,043 sarcoma tumor specimens, and 50% were found to be Rb-positive. Using in vitro and in vivo models, an effective two-step sequential combination strategy was developed. Abemaciclib was used first to prime Rb-positive sarcoma cells to reversibly arrest in G1 phase. Upon drug removal, cells synchronously traversed to S phase, where a second treatment with S-phase targeted agents (gemcitabine or Wee1 kinase inhibitor) mediated a synergistic response by inducing DNA damage. The response to treatment could be noninvasively monitored using real-time positron emission tomography imaging and serum thymidine kinase activity. Collectively, these results show that a novel, sequential treatment strategy with a CDK4/6 inhibitor followed by a DNA-damaging agent was effective, resulting in synergistic tumor cell killing. This approach can be readily translated into a clinical trial with noninvasive functional imaging and serum biomarkers as indicators of response and cell cycling.Significance:An innovative sequential therapeutic strategy targeting Rb, followed by treatment with agents that perturb DNA synthesis pathways, results in synergistic killing of Rb-positive sarcomas that can be noninvasively monitored.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
Treatment strategies with a strong scientific rationale based on specific biomarkers are needed to improve outcomes in patients with advanced sarcomas. Suppression of cell-cycle progression through reactivation of the tumor suppressor retinoblastoma (Rb) using CDK4/6 inhibitors is a potential avenue for novel targeted therapies in sarcomas that harbor intact Rb signaling. Here, we evaluated combination treatment strategies (sequential and concomitant) with the CDK4/6 inhibitor abemacicib to identify optimal combination strategies. Expression of Rb was examined in 1,043 sarcoma tumor specimens, and 50% were found to be Rb-positive. Using in vitro and in vivo models, an effective two-step sequential combination strategy was developed. Abemaciclib was used first to prime Rb-positive sarcoma cells to reversibly arrest in G1 phase. Upon drug removal, cells synchronously traversed to S phase, where a second treatment with S-phase targeted agents (gemcitabine or Wee1 kinase inhibitor) mediated a synergistic response by inducing DNA damage. The response to treatment could be noninvasively monitored using real-time positron emission tomography imaging and serum thymidine kinase activity. Collectively, these results show that a novel, sequential treatment strategy with a CDK4/6 inhibitor followed by a DNA-damaging agent was effective, resulting in synergistic tumor cell killing. This approach can be readily translated into a clinical trial with noninvasive functional imaging and serum biomarkers as indicators of response and cell cycling.Significance:An innovative sequential therapeutic strategy targeting Rb, followed by treatment with agents that perturb DNA synthesis pathways, results in synergistic killing of Rb-positive sarcomas that can be noninvasively monitored.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
Supplementary Table S3 lists the baseline demographics, clinical and prior treatment characteristics of the prospective RMC cohort used in the study.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
Supplementary Table S3 lists the baseline demographics, clinical and prior treatment characteristics of the prospective RMC cohort used in the study.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
This pdf file contains Supplementary Figures S1-S5 and their legends.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
This pdf file contains Supplementary Figures S1-S5 and their legends.